Efficacy and Safety of Pregabalin in Neuropathic Pain Followed Spinal Cord Injury A Review and Meta-Analysis of Randomized Controlled Trials

doi:10.1097/AJP.0000000000000675

CORC > 金属研究所 > 中国科学院金属研究所

	Efficacy and Safety of Pregabalin in Neuropathic Pain Followed Spinal Cord Injury A Review and Meta-Analysis of Randomized Controlled Trials
	Yu, Xiaobing 1,2,3; Liu, Tao 2; Zhao, Dewei 2,3; Yang, Ke 1; Zhang, Xiuzhi 2; Zhang, Meng 2; Zhang, Shuo 2; Huang, Wei 2; Wu, Baolin 2; Li, Junlei 2
刊名	CLINICAL JOURNAL OF PAIN
	2019-03-01
卷号	35 期号:3 页码:272-278
关键词	pregabalin neuropathic pain spinal cord injury efficacy mata-analysis
ISSN号	0749-8047
DOI	10.1097/AJP.0000000000000675
通讯作者	Yu, Xiaobing(dldxyxb@163.com)
英文摘要	Objective: Pregabalin has been approved for the treatment of the neuropathic pain following spinal cord injury (SCI). We performed a systemic review and meta-analysis of randomized, controlled, multicenter trials to evaluate the efficacy and safety of pregabalin for SCI-induced neuropathic pain. Materials and Methods: Research searching was performed in PubMed and EMBASE databases and the Cochrane library in May 2018. Clinical controlled trials using pregabalin for the pain treatment following SCI in adults (18 y old and above) were included. Pain and safety-related adverse events were considered as outcomes. Meta-analysis was conducted using Revman 5.0 software. Results: Five publications (pregabalin, patients=261, placebo, patients=216) were included in our study. After at least 4-week's treatment with pregabalin (flexible dose, 150 to 600 mg/d), pregabalin-treated patients showed reduced pain -1.54, 95% confidence interval (CI) (-2.33, -0.75), P=0.0001; improved >30% 1.83, 95% CI (1.37, 2.46), P50% pain relief 2.40, 95% CI (1.53, 3.77), P=0.0001; increased adverse events 1.36, 95% CI (1.18, 1.577), P<0.0001; and reduced Hospital Anxiety and Depression Scale - anxiety -1.50, 95% CI (-2.99, -0.00), P=0.05 and - depression -0.34, 95% CI (-0.55, -0.12), P=0.002 scores compared with placebo-treated patients. Stratified meta-analysis showed there was no difference in primary adverse events (drowsiness, dizziness, peripheral edema, and dry mouth) between pregabalin and placebo groups (P >= 0.05). Conclusions: Our results showed pregabalin was efficacious and might be safe treatment for chronic pain followed SCI.
WOS研究方向	Anesthesiology ; Neurosciences & Neurology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000459157400009
内容类型	期刊论文
源URL	[http://ir.imr.ac.cn/handle/321006/131946]
专题	金属研究所_中国科学院金属研究所
通讯作者	Yu, Xiaobing
作者单位	1.Chinese Acad Sci, Inst Met Res, Shenyang, Liaoning, Peoples R China 2.Dalian Univ, Zhongshan Hosp, Dept Orthopaed, Dalian, Peoples R China 3.Dalian Univ, Zhongshan Hosp, Postdoctoral Workstn, Dalian, Peoples R China
推荐引用方式 GB/T 7714	Yu, Xiaobing,Liu, Tao,Zhao, Dewei,et al. Efficacy and Safety of Pregabalin in Neuropathic Pain Followed Spinal Cord Injury A Review and Meta-Analysis of Randomized Controlled Trials[J]. CLINICAL JOURNAL OF PAIN,2019,35(3):272-278.
APA	Yu, Xiaobing.,Liu, Tao.,Zhao, Dewei.,Yang, Ke.,Zhang, Xiuzhi.,...&Li, Junlei.(2019).Efficacy and Safety of Pregabalin in Neuropathic Pain Followed Spinal Cord Injury A Review and Meta-Analysis of Randomized Controlled Trials.CLINICAL JOURNAL OF PAIN,35(3),272-278.
MLA	Yu, Xiaobing,et al."Efficacy and Safety of Pregabalin in Neuropathic Pain Followed Spinal Cord Injury A Review and Meta-Analysis of Randomized Controlled Trials".CLINICAL JOURNAL OF PAIN 35.3(2019):272-278.